Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

BOSTON--(BUSINESS WIRE)--Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the first ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

According to TipRanks, Bell is an analyst with an average return of -7.6% and a 50.00% success rate. The word on The Street in general, suggests a Hold analyst consensus rating for Synthomer with a ...

First-in-human data with investigational formulation of SYNT-101 establish preliminary safety, tolerability and efficacy markers, including modulation of hunger hormones Preclinical weight loss data ...

Synthomer PLC Quarterly cash flow by MarketWatch. View SYNT net cash flow, operating cash flow, operating expenses and cash dividends.

Researchers at the RIKEN Cluster for Pioneering Research (CPR) have developed technology that can alter, within the body, the recognized identity of proteins. The innovation, published in Nature ...

Get an expert wealth review to identify gaps in your portfolio. The Estimates data displayed by Moneycontrol is not a recommendation to buy or sell any securities. Estimates data is a third party ...

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses more than once in a while. So spare a thought for the long term shareholders of ...

Synthomer (LON: SYNT) shares are down another 4% on the news of the clean up of the rights issue. The underwriters have managed to get those new shares away at the issue price that is. We might ...